Eli Lilly (LLY) said Tuesday it doesn't have any affiliation with Hims & Hers Health (HIMS), adding that its weight-loss drug Zepbound, or tirzepatide, can be prescribed by "any licensed healthcare professional."
Hims & Hers earlier said it was expanding its weight-loss products on its telehealth platform to include generic liraglutide and branded tirzepatide.
Hims & Hers shares were down 4.9% in recent premarket activity Wednesday, while Lilly fell 0.3%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.